Author Interviews, Infections / 01.04.2024

MedicalResearch.com Interview with: Maria Y. Tian, MBS Department of Medical Education Geisinger Commonwealth School of Medicine Scranton PA MedicalResearch.com: What is the background for this study? Response: The antibiotic crisis continues to worsen in the United States (U.S.), which has seen an increasing number of deaths associated with antibiotic resistance, becoming one of the most pressing threats to public health. Concurrently, the availability of effective antibiotics are decreasing, which increases the rates and severity of infections, particularly in patients with respiratory tract infections. Unfortunately, a persistent and pernicious contributing factor to the crisis is the unnecessary prescription of antibiotics. In a previous study, 25% of antibiotics prescribed in the outpatient setting to Medicaid beneficiaries were not associated with a provider visit [2]. Furthermore, among 298 million prescriptions filled by 53 million Medicaid patients between 2004 and 2013, 45% of the prescriptions for antibiotics were made without any clear rationale [2]. In our study, we aimed to provide an up-to-date analysis of antibiotic prescribing in the U.S. through examining the temporal profile of outpatient antibiotic use reported by Medical Expenditure Panel System (MEPS) and geographical patterns of antibiotic prescribing rates among US Medicaid program beneficiaries. This will help identify potentially unnecessary prescriptions and inform stewardship efforts. (more…)
Author Interviews, COVID -19 Coronavirus / 10.07.2023

MedicalResearch.com Interview with: Fernanda Lessa, MD, MPH Chief, CDC’s International Infection Control Program Co-author of the paper MedicalResearch.com: What is the background for this study? What are the main findings? Response: Data from low- and middle-income countries on the impact of the COVID-19 pandemic on antibiotic use among outpatients are sparse. This study evaluated the changes in prescribing rates of antibiotics commonly prescribed for respiratory tract infections by outpatient providers among adults in Brazil. We observed increases during the pandemic in outpatient prescriptions of azithromycin and ceftriaxone of up 360% and 90%, respectively, based on age and sex. (more…)
Author Interviews, CDC, Infections / 07.12.2021

MedicalResearch.com Interview with: Michael Craig MPP Director, Antibiotic Resistance Coordination and Strategy CDC  MedicalResearch.com: What is the mission of the Global Action in Healthcare Network (GAIHN)? How will it work to coordinate detection and response efforts across multiple countries and cultures? 
  • Health care can often be an epicenter of infectious disease outbreaks that can spread within a facility, between facilities, and beyond the facility into the community. CDC’s Global Action in Healthcare Network (GAIHN) consists of countries, healthcare facilities, and public health partners working together to prevent, detect, and respond to infectious disease threats in the healthcare setting. GAIHN will target health care threats like antimicrobial-resistant infections, healthcare-associated infections (HAIs), and COVID-19 through infection prevention and control.
  • Close coordination across experts at CDC, and strong relationships and communications with our funded partners, international colleagues, ministries of health and country leadership, will make GAIHN successful and ensure collaboration, minimize duplication, and maximize advancements across countries and cultures.
  • Find more information about the 2021 GAIHN projects: https://www.cdc.gov/infectioncontrol/global/GAIHN.html 
(more…)
Author Interviews, Cancer Research, Colon Cancer / 02.09.2021

MedicalResearch.com Interview with: Sophia Harlid, Ph.D. Associate Professor/Docent in Molecular Epidemiology Department of Radiation Sciences Umeå University Umeå, Sweden MedicalResearch.com: What is the background for this study? Response: Antibiotics has previously been associated with in increased risk of colorectal cancer, with this study we were able to use comprehensive registry data to further break down and validate this relationship.  (more…)
Author Interviews, Infections / 11.07.2021

MedicalResearch.com Interview with: Juliana Menezes MSc I am a PhD student at the Faculty of Veterinary Medicine of the University of Lisbon. I do my research at the Centre for Interdisciplinary Research in Animal Health under the Supervision of Professor Constança Pomba, the head of the Antibiotic Resistance Lab. The Idea for this work came from my supervisor, that has been working in the field of antibiotic resistance for a while and was leading a research project, the Pet-Risk consortium (http://petrisk.fmv.ulisboa.pt/) which main goal was to evaluate sharing of resistant bacteria between animal and humans (namely ESBL). Following this idea, we thought that would be important to evaluate colistin resistance in animals.” MedicalResearch.com: What is the background for this study? Response: With the global spread of multi-drug carbapenem resistant Gram-negative bacteria, colistin is a last-resort antimicrobial to treat ICU patients in hospitals. Thus, WHO has classified Colistin as a Highest Priority Critically Important Antimicrobial for human medicine, therefore, resistance represents a serious concern among physicians and scientists.  Increasing trends and prevalence of colistin resistance have been observed worldwide, and the studies are mainly focused on food-producing animals or hospitalized humans, suggesting an exchange of pathogenic bacteria and/or mobile genetic elements between different reservoirs. The rational for this study is the importance to evaluate colistin resistance in companion animals as they are living in direct contact with humans in the community. (more…)
Author Interviews, JAMA, Surgical Research / 08.01.2021

MedicalResearch.com Interview with: Melina R. Kibbe, MD, FACS, FAHA Colin G. Thomas Jr. Distinguished Professor and Chair Department of Surgery Professor, Department of Biomedical Engineering The University of North Carolina at Chapel Hill Chapel Hill, NC 27599-7050 MedicalResearch.com: What is the background for this study? What are the main findings? Response: Fluoroquinolones are a commonly prescribed antibiotic.  Recent data from Taiwan, Sweden, and Canada suggests that the use of fluoroquinolones increase the short-term risk of aneurysm formation in certain older patient  populations.  As such, the FDA issued a warning in 2018 regarding the use of fluoroquinolone antibiotics suggesting that this class of antibiotics should not be used in patients at increased risk. The FDA defined the high risk population as those with a history of aneurysms or blockages, high blood pressure, certain genetic disorders related to blood vessels, and the elderly.  However, we hypothesized that this risk of taking fluoroquinolones extends to all patient populations and not just high risk patient populations.  (more…)
Author Interviews, Infections, JAMA / 08.09.2020

MedicalResearch.com Interview with: Yaa-Hui Dong PhD Faculty of Pharmacy National Yang-Ming University Taipei, Taiwan MedicalResearch.com: What is the background for this study? Response: Previous observational studies found that fluoroquinolones may be associated with more than 2-fold increased risk of aortic aneurysm or aortic dissection (AA/AD). However, these studies might not well address the influence of concurrent infection, which is also a suggested risk factor for AA. Moreover, most of these studies compared fluoroquinolone use versus no fluoroquinolone use, which might overestimate the risk with fluoroquinolones as patients on fluoroquinolones may have more severe infection versus those not on fluoroquinolones. (more…)
Author Interviews, Clots - Coagulation, NEJM / 12.08.2020

MedicalResearch.com Interview with: Elizabeth Webb, M.P.H Physiotherapy Department Calvary Public Hospital Bruce Bruce, Australia MedicalResearch.com: What is the background for this study? Response: Our study showed that in patients with a history of leg swelling (chronic edema), compression therapy by a skilled lymphedema therapist reduced the risk of infection in the leg (cellulitis) by a huge 77%. With up to 47% of patients experiencing recurrence of cellulitis in their legs within 3 years, this result is a game-changer in terms of our approach to managing patients with leg swelling and recurrent cellulitis. Until now, the use of prophylactic antibiotics to prevent cellulitis has been the only evidence-based practice. We know however, there are many reasons why avoidance of antibiotics is important within our community. (more…)
Author Interviews, JAMA, Pediatrics, Weight Research / 29.01.2020

MedicalResearch.com Interview with: Dr. Carol Chelimo PhD Research Fellow Dept. of Paediatrics, School of Medicine University of Auckland MedicalResearch.com: What is the background for this study? Response: New Zealand has the third highest prevalence of obesity among Organisation for Economic Co-operation and Development countries. Pediatric obesity is associated with development of cardiovascular risk factors in later life, such as type 2 diabetes, hypertension, dyslipidemia, and metabolic syndrome. Antibiotic exposures in early life may affect weight by altering the gut microbiota, potentially increasing the risk of childhood obesity. The overall aim of this research was to examine whether repeated antibiotic exposure by age 48 months is associated with higher body mass index (BMI) at age 54 months. Specifically, it evaluates whether the number, timing (age), and type of antibiotic exposures are associated with a higher body mass and an increased likelihood of overweight and obesity. This work incorporates antibiotic exposure during pregnancy (more…)
Allergies, Author Interviews, C. difficile, Dental Research, Infections / 05.10.2019

MedicalResearch.com Interview with: Alan E. Gross, PharmD Clinical Assistant Professor University of Illinois Chicago, IL MedicalResearch.com: What is the background for this study? Response: Dentists prescribe 10% of all outpatient antibiotics. Most of this prescribing is for infection prophylaxis prior to dental procedures. Our prior research has found that 80% of prescriptions for dental prophylaxis is unnecessary. Although antibiotic prophylaxis prior to dental procedures is often for a short course (e.g. one time amoxicillin dose), there may be patient harm associated with this. (more…)
Author Interviews, Biomarkers, NEJM, Pulmonary Disease / 11.07.2019

MedicalResearch.com Interview with: Dr. Chris Butler,, BA MBChB DCH CCH MD FRCGP (Hon)FFPH FMedSci Professor of Primary Care Nuffield Department of Primary Care Health Sciences, Professorial Fellow at Trinity College Clinical Director Primary Care Clinical Trials Unit University of Oxford  MedicalResearch.com: What is the background for this study? Response: More than a million people in the UK have COPD, which is a lung condition associated with smoking and other environmental pollutants. People living with the condition often experience exacerbations, or flare-ups, and when this happens, three out of four are prescribed antibiotics. However, two-thirds of these flare-ups are not caused by bacterial infections and antibiotics often do not benefit patients. A simple finger-prick blood test could help prevent unnecessary prescribing of antibiotics for people with the lung condition chronic obstructive pulmonary disease (COPD).  The finger-prick test measures the amount of C- reactive protein (CRP) - a marker of inflammation that rises rapidly in the blood in response to serious infections. People with a COPD flare-up who have a low CRP level in the blood appear to receive little benefit from antibiotic treatment. The General Practitioner (GP) use of a C-Reactive Protein (CRP) Point of Care Test (POCT) to help target antibiotic prescribing to patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) who are most likely to benefit (The PACE Study) determined whether the using a POCT CRP to guide antibiotic treatment decisions for acute exacerbations of COPD reduced antibiotic use without harming patients. (more…)
Annals Internal Medicine, Author Interviews, Infections, University of Michigan / 09.07.2019

MedicalResearch.com Interview with: Valerie M. Vaughn, MD MSc Assistant Professor of Medicine and Research Scientist, Division of Hospital Medicine The Patient Safety Enhancement Program and Center for Clinical Management Research Michigan Medicine and the Ann Arbor VA Medical Center  MedicalResearch.com: What is the background for this study? Response: Pneumonia is one of the top causes for hospitalization and one of the main reasons for antibiotic use in US hospitals. In the past decade, studies have suggested that patients can be safely treated with short course antibiotic therapy instead of the prolonged courses we used to prescribe. Our study looked at prescribing practices in 43 hospitals across the state of Michigan to see if we were appropriately prescribing short course therapy, and if so, how that affected patients. (more…)
Author Interviews, Infections / 24.06.2019

MedicalResearch.com Interview with: David Houston PhD Senior Scientist and wound project Neem Biotech MedicalResearch.com: What is the background for this study?   Response: Biofilms are complex bacterial communities formed during the natural infection process as a protection mechanism and controlled by bacterial quorum sensing. These biofilm communities allow infections to spread by producing toxins that inhibit the body’s immune system, generating exopolysaccharide and changes in metabolic state that reduce the efficacy of antibiotics and activating virulence factors, which ultimately drive the spread of infection. Stopping the spread of infection by inhibition of quorum sensing has potential to manage a wide range of infections, including in wounds. In chronically-infected wounds, the prevention of biofilm formation, disruption of mature biofilms, reduction of virulence factors and thereby the spread of infection remains clinically elusive. Quorum sensing (QS) pathways regulate microbial motility, virulence factor production and the formation and maturation of biofilms. Inhibiting QS therefore presents a potential mode of therapeutic intervention for infections. (more…)
Author Interviews, Dermatology, Infections, JAMA / 19.06.2019

MedicalResearch.com Interview with: Richard Brindle DM FRCP Honorary Reader, University of Bristol, UK  MedicalResearch.com: What is the background for this study? Response: This review is an update of the 2010 Cochrane Review of Interventions for cellulitis and erysipelas (DOI: 10.1002/14651858.CD004299) but focusing on antibiotics.  It provides a valuable resource for clinicians in summarizing current best evidence and highlighting gaps in the research. This review will inform the production of evidence-based guidelines covering antibiotic choice, route of administration, duration of treatment and the role of combinations of antibiotics. (more…)
Author Interviews, Dental Research / 02.06.2019

MedicalResearch.com Interview with: Dr. Katie Suda, PharmD, M.S.  Associate Professor College of Pharmacy University of Illinois at Chicago  MedicalResearch.com: What is the background for this study? Response: Dentists prescribe approximately 1 in every 10 antibiotics in the United States and are the top specialty prescriber. Dentists are the primary prescriber of clindamycin in the U.S., which is associated with a high risk of C. difficile infection (an overgrowth of bacteria in the GI tract that can cause a life-threatening infection). Clinical guidelines recommend that patients with specific cardiac conditions receive a dose of antibiotics prior to undergoing invasive dental procedures to prevent infective endocarditis (an infection of the heart values). Taking a dose of antibiotics prior to a dental visit is referred to as antibiotic prophylaxis. Starting in 2007, these guidelines were narrowed secondary to poor evidence on the effectiveness of antibiotic prophylaxis and the risk of antibiotic-related adverse events. Antibiotic adverse events include antibiotic resistance, C. difficile infection, and other general adverse events (nausea, vomiting, diarrhea). While significant research has been conducted on unnecessary prescribing of antibiotics by medical providers, little work has described appropriateness of prescribing by dentists. We assessed if antibiotics prescribed for prophylaxis prior to dental procedures were consistent with clinical guidelines. (more…)
Author Interviews, Heart Disease, Women's Heart Health / 29.04.2019

MedicalResearch.com Interview with: Dr. Lu Qi MD PhD Department of Epidemiology, School of Public Health and Tropical Medicine Tulane University New Orleans, LA 70112 Department of Nutrition, Harvard T.H. Chan School of Public Health, Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School Boston, MA 02115 Yoriko Heianza RD, PhD Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University New Orleans, LA  MedicalResearch.com: What is the background for this study? What are the main findings?  Response: Growing data suggest that antibiotic exposure is associated with a long-lasting alteration in gut microbiota, and may be related to subsequent cardiovascular disease (CVD). We investigated associations of duration of antibiotic use in different phases of adulthood (young, middle and late adulthood) with the CVD incidence among women at usual risk. This new analysis from the Nurses’ Health Study shows that women who take antibiotics for long periods, especially during more recent adulthood (such as  in middle- and late adulthood) had a higher risk of CVD in later life.  (more…)
Author Interviews / 18.03.2019

MedicalResearch.com Interview with: Darwin Chen, MD Assistant Professor of Orthopedic Surgery Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? What are the main findings? Response: Periprosthetic joint infection unfortunately remains a leading cause of total knee arthroplasty failure. One method of mitigating the risk of PJI is to use antibiotic loaded bone cement in a prophylactic fashion. While the use of antibiotic cement makes inherent sense, the decision is not as simple as it seems. There are potential side effects such as renal damage, antibiotic hypersensitivity, and antibiotic resistance. Antibiotics decrease the mechanical strength of cement fixation, which may impact component loosening. Additionally, antibiotic cement is significantly more expensive than standard cement, driving up cost. Currently there is no consensus on if antibiotic cement truly reduces infection risk and there are many conflicting studies. The purpose of our study is the use a large national database to evaluate real world utilization patterns of antibiotic cement, and assess outcomes, complications, and cost associated with antibiotic cement usage. Our hypothesis was that antibiotic cement is associated with a decreased risk of infection and no increased risk of systemic complications.  (more…)
Author Interviews, Dermatology, JAMA, Johns Hopkins, Microbiome / 15.02.2019

MedicalResearch.com Interview with: Luis Garza, MD-PhD Associate Professor Department of Dermatology Johns Hopkins School of Medicine Baltimore, MD 21287 MedicalResearch.com: What is the background for this study? What are the main findings?  Do you think these findings would be similar with other antibiotics (oral or topical) or with isotretinoin for acne? Response: We prescribe antibiotics frequently for acne. We certainly know it affects our normal and abnormal bacteria on our skin. But we don’t fully understand how well or not people recover from antibiotics.  (more…)
Antibiotic Resistance, Asthma, Author Interviews, JAMA / 04.02.2019

MedicalResearch.com Interview with: Mihaela S Stefan, MD, PhD FACP Research Scientist, Institute for Healthcare Delivery and Population Science Associate Professor, UMMS-Baystate Director of Perioperative Clinic and Medical Consultation Program Academic Hospitalist Director Quality Assessment, Division of Healthcare Quality Springfield MA MedicalResearch.com: What is the background for this study? What are the main findings? Response: In a prior study we have found that roughly 41% of patients hospitalized with an asthma exacerbation receive antibiotics although the guidelines do not support this practice. We found that the evidence supporting the guidelines was however limited to 6 trials which included a total of only 681 adults and children and most trials’ outcomes were symptoms or lung function not length of stay, need for mechanical ventilation, readmissions or death. We performed the largest observational study to-date of approximately 20 000 patients hospitalized for asthma exacerbation and found that patients treated with antibiotics did not have better outcomes but instead they had longer hospital stay and an increased risk for antibiotic-related diarrhea. (more…)
Author Interviews, Gastrointestinal Disease, Microbiome, Nature / 11.01.2019

MedicalResearch.com Interview with: Dr. Venkatakrishna R Jala, PhD Assistant Professor James Graham Brown Cancer Center Department of Microbiology and Immunology University of Louisville MedicalResearch.com: What is the background for this study? What are the main findings? Response: Humans evolved along with their gut microbiota and adapted their physiological activities to help each other. Along with consumption of healthy diets, humans must harbor the appropriate microbiota to convert the foods into available components called metabolites. These microbial metabolites play a critical role in preserving homeostasis, the development of immune systems and preventing adverse events both systemically and locally. Despite the availability of large metagenomics (bacterial sequence) data, and its associations with disease conditions, the functional dynamics of microbiota (good vs bad) in human health or diseases are yet to be defined. The host’s indigenous gut microbiota and its metabolites have emerged as key factors that greatly influence human health and disease, including inflammatory bowel diseases (IBD). IBD patients suffer from leaky gut and increased inflammation. The current study demonstrates that a microbial metabolite derived from ellagitannin/ellagic acid rich diets (e.g., pomegranate, berries) called ‘urolithin A’ and its synthetic analogue significantly enhance gut barrier function in addition to blocking the unwarranted inflammation in IBD animal models.  (more…)
Author Interviews, Infections, Pediatrics, Pulmonary Disease / 08.11.2018

MedicalResearch.com Interview with: Andrea Hahn, M.D., MS Infectious disease specialist and lead study author Children's National Health System MedicalResearch.com: What is the background for this study? What are the main findings? Response: People who have the genetic disease cystic fibrosis have increased sticky secretions in their lungs that put them at risk for repeated bacterial infections. They often will receive courses of intravenous antibiotics to treat more severe or difficult-to-treat infections associated with decreased lung function. However, not all patients fully recover their lung function after antibiotic treatment, despite directing antibiotic therapy toward the specific bacteria thought to be causing the infection. The goal of this study was to determine if the pharmacokinetics of commonly used antibiotics was associated with recovery of lung function. First, we found that patients with therapeutic blood levels of beta-lactam antibiotics had better lung recovery than patients with sub-therapeutic levels of these antibiotics. Second, we found that using higher antibiotic dosing according to Cystic Fibrosis Foundation guidelines was not sufficient to predict which patients would have therapeutically meaningful blood levels of antibiotics. (more…)
Author Interviews, NEJM, STD / 07.11.2018

MedicalResearch.com Interview with: Edward W. Hook, III, MD University of Alabama at Birmingham Medicine / Infectious Diseases Birmingham, AL MedicalResearch.com: What is the background for this study? What are the main findings? Response: Zoliflodacin represents a new class of antibiotics (spiropyrimidinetriones) with in vitro activity against Neisseria gonorrhoeae, as well as other STD  pathogens (Chlamydia trachomatis and Mycoplasma genitalium).  Because of this promising data and the fact that the manufacturer (Entasis Pharmaceuticals) was willing to pursue the possibility of using this drug to treat gonorrhea, a Phase II trial was conducted which showed he drug to be 96% effective for genital or rectal infections.  The drug was well tolerated as well making it a promising drug for gonorrhea treatment which might help to combat the increasing problem of antibiotic resistant gonorrhea.  (more…)
Author Interviews, Global Health, Hospital Acquired, Infections, Lancet / 07.11.2018

MedicalResearch.com Interview with: "Antibiotics" by Michael Mortensen is licensed under CC BY-SA 2.0Dr Alessandro Cassini MD Epidemiologist, European Centre for Disease Prevention and Control Solna, Sweden MedicalResearch.com: What is the background for this study? Response: We published an ECDC study estimating attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the European Union and the European Economic Area (EU/EEA). This study is based on 2015 data from the European Antimicrobial Resistance Surveillance Network (EARS-Net). The study was developed by experts at ECDC and the Burden of AMR Collaborative Group, and published in The Lancet Infectious Diseases. (more…)
Author Interviews, BMJ, Pediatrics, Weight Research / 01.11.2018

MedicalResearch.com Interview with: "babies (365-222)" by Robert Couse-Baker is licensed under CC BY 2.0Dr. Christopher M Stark Department of Pediatrics William Beaumont Army Medical Center El Paso, Texas Department of Pediatrics Walter Reed National Military Medical Center Bethesda, Maryland MedicalResearch.com: What is the background for this study? What are the main findings?  Response: Rates of pediatric obesity have increased over the past decade, which has led researchers to search for modifiable risk factors that may explain this increase. Recent studies have identified an association between native gut bacteria alterations and the development of obesity. Several population-based studies have evaluated whether or not there is an association between antibiotic exposure and the development of obesity, with mixed results. No studies have previously evaluated if acid suppressing medications are associated with developing obesity. We found that young children prescribed antibiotics, acid suppressants, and combinations of these medications in the first two years of life are more likely to develop obesity after two years of age. Our study represents the largest study to evaluate pediatric antibiotic prescriptions and obesity risk, with nearly ten times as many patients as the next largest study. (more…)
Author Interviews, Infections, Lancet, Urinary Tract Infections / 27.10.2018

MedicalResearch.com Interview with: https://www.shionogi.com/Simon Portsmouth, MD Senior Medical Director Shionogi Inc. MedicalResearch.com: What is the background for this study? What are the main findings? Response: Antibiotics for multidrug resistant  Gram-negative infections are desperately needed. Cefiderocol is the first siderophore antibiotic to reach patients. Siderophore antibiotics bind to free iron and use the bacterial active iron transport channels to cross the outer membrane of Gram-negative bacteria. Laboratory studies have shown that cefiderocol is active against multi-drug resistant Gram-negative bacteria, often where no other antibiotics are active. It is able to overcome most types of antibiotic resistance due to its active transport into cells and stability against all carbapenemases. The need for antibiotics for carbapenem resistant Gram-negative infections is described as a critical need by the WHO. This trial was the first in humans with serious infections and demonstrated excellent efficacy in a complicated patient population where almost ¼ were over 75 years of age. Additionally cefiderocol did not appear to have any safety problems, and was well tolerated. (more…)
Author Interviews, Baylor College of Medicine Houston, JAMA, Surgical Research / 12.10.2018

MedicalResearch.com Interview with: Scott A. LeMaire, MD Jimmy and Roberta Howell Professor of Cardiovascular Surgery Vice Chair for Research, Michael E. DeBakey Department of Surgery Professor of Molecular Physiology and Biophysics Director of Research, Division of Cardiothoracic Surgery Baylor College of Medicine Department of Cardiovascular Surgery Texas Heart Institute Baylor St. Luke’s Medical Center CHI St. Luke’s Health Editor-in-Chief, Journal of Surgical Research MedicalResearch.com: What is the background for this study? What are the main findings? Response: We performed this study because of concerns about the potential association between fluoroquinolones and aortic aneurysms and dissection raised in two large clinical studies. This concern was noted by the US Food and Drug Administration in May 2016, but the evidence was not deemed sufficient to warrant a warning. Hence, there was a clear need for additional studies to evaluate the problem. Our study was designed to determine whether there is biological evidence that ciprofloxacin—the most commonly prescribed fluoroquinolone—exacerbates aortic disease in a well-established mouse model. The model uses high-fat diet and angiotensin II infusion to stress the aorta and cause aneurysm and dissection. Using this model, we compared mice that received ciprofloxacin to control mice that received only vehicle, and we found that mice that received ciprofloxacin had significant increases in the incidence of aortic dilatation, severe aortic aneurysm and dissection, and aortic rupture and premature death. Importantly, these findings were consistent in male and female mice. Further, we investigated the potential underlying mechanisms and found that the aortas from mice that received ciprofloxacin had decreased levels of lysyl oxidase, increased levels of matrix metalloproteinases, and increased levels of apoptosis and necroptosis. (more…)
Author Interviews, Dermatology, Pharmaceutical Companies / 09.10.2018

MedicalResearch.com Interview with: foamixDavid Domzalski CEO Foamix Pharmaceuticals MedicalResearch.com: What is the background for this study?  How does FMX101 differ from other treatment for acne, ie benzoyl peroxide, topical clindamycin etc?  Response: This study measures the safety and efficacy of a topical foam formulation of the antibiotic minocycline, for the treatment of moderate-to-severe acne. Minocycline is one of the most commonly used products for the treatment of acne, but is currently only available in an oral dosage form. Significant side effects are associated with oral minocycline, including GI upset, photosensitivity, headaches, dizziness, and other potential effects on the CNS.  In addition to the side effects associated with oral minocycline, many currently available topical acne medications contain ingredients which can be drying and irritating to the skin.  These side effects can be frustrating to patients and potentially impact overall compliance to their treatment regimen.  The study addresses important unmet needs in dermatology to determine whether providing patients with a topical dosage form of minocycline may have potential advantages over existing products. In our first two Phase 3 clinical studies, >95% of facial local tolerability signs and symptoms were classified as “none” or “mild,” including dryness, erythema and itching.  Also, our topical minocycline foam, FMX101, is a natural triglyceride-based vehicle that does not contain ingredients that serve as  primary irritants or surfactants.  We believe that FMX101, if approved, would be the first topical minocycline available for the treatment of acne and provide a novel and much needed treatment option for patients who suffer from the physical and psycho-social effects of acne. (more…)
Antibiotic Resistance, Author Interviews, Infections / 08.10.2018

MedicalResearch.com Interview with: David G. Thanassi, Ph.D. Professor and Interim Chair Department of Molecular Genetics & Microbiology Center for Infectious Diseases Stony Brook University Stony Brook, NY 11794-5222 MedicalResearch.com: What is the background for this study? What are the main findings? Response: Pathogenic bacteria such as Escherichia coli use hair-like surface appendages termed pili to colonize tissues within the host and initiate infection.  Together with our collaborators - the group of Huilin Li at the Van Andel Research Institute - we used an advanced imaging technique termed cryo-electron microscopy to determine snapshots of bacterial pili as they are being assembled.  The pili we studied are critical for uropathogenic strains of E. coli to colonize the urinary tract and cause urinary tract infections.  Our work revealed a new stage in the pilus assembly process and new details about how these structures are built on the bacterial surface.   (more…)
Author Interviews, C. difficile, Critical Care - Intensive Care - ICUs, Infections / 07.10.2018

MedicalResearch.com Interview with: Richard Hengel, MD, FRCPC, FACP Atlanta ID Group Richard Hengel, MD, FRCPC, FACP Atlanta ID Group MedicalResearch.com: What is the background for this study? How does Bezlotoxumab differ from other medications for recurrent C. difficile infections? Response: Clostridium difficile infection (CDI) is now the most common hospital acquired infection in the United States, accounting for significant morbidity and mortality, not only in the US, but around the world. Despite standard antibiotic therapy targeting the Clostridium difficile bacterium directly, recurrent infection is common, occurring in a quarter to a third of patients, often frail individuals with other concurrent medical problems. These patients can have multiple recurrences leading to their progressive deterioration over time. Until recently, the only treatment for CDI included antibiotics. More recently, fecal microbiota transplant is a promising, but as yet, FDA unapproved therapy. Bezlotoximab is a new FDA approved treatment for recurrent Clostridium difficile infection (rCDI) that compliments standard antibiotics. Bezlotoxumab is a monoclonal antibody targeting toxin B produced by Clostridium difficile during CDI. In two large treatment trials, bezotoxumab, in addition to standard-of-care antibiotics, reduced the frequency of CDI recurrences from about 28% to about 18%. In this study, we set out to see if this new drug performed as well in actual clinical practice as it did in the published clinical trials. (more…)